Amphion Innovations plc Interim Results
Show 21 Percent Gain in Fair Value of Investments

NEW YORK, September 7, 2006 - Amphion Innovations plc (LSE:AMP) (“Amphion” or “the Company”), the developer of technology and life sciences businesses, today announces its unaudited interim results for the period from 1 January 2006 to 30 June 2006.

Financial Highlights

Operating Highlights (Pre-30 June)

Operating Highlights (Post-30 June)

Amphion Chief Executive Officer Richard C. E. Morgan, said:
“During this period we have seen tremendous momentum in the key areas of our business model, which is to develop thriving companies.

“There has been significant activity in capital raising and we have continued to acquire groundbreaking intellectual property (IP) in life sciences. These are the key factors fuelling our underlying engine of growth as indicated by the 21 percent increase in fair value of our investment portfolio. The successful fundraisings, in excess of US $8 million, along with the acquisition of talent and IP, have underpinned our commitment to growth and are a true validation of our strategy to continue to grow our seven Partner Companies. The latest planned addition to our portfolio, Myconostica Ltd. shows our continued dedication to finding new commercial opportunities in the universities and adding one company to the Amphion portfolio per year, while maintaining a portfolio of 7 to 10 Partner Companies at any one time.”

Amphion Interim Financial Statement - PDF48k PDF
Notes on above - PDF117k PDF


For further information please contact

Amphion Innovations plc
Josh Berkman, Media Relations
+1 (646) 747-7158

Financial Dynamics
Ben Atwell / John Gilbert

Notes to editors

About Amphion Innovations
Working in partnership with universities and corporations seeking to commercialise their intellectual property, Amphion Innovations plc utilises a proven company creation and building process, staying deeply involved with its Partner Companies before seeing them through a public offering or trade sale.

Amphion currently holds a significant stake in each of its Partner Companies, is continually evaluating new opportunities, and expects to add Myconostica Ltd as a Partner Company in 2006.

On the web:


Overview for 1 January 2006 – 30 June 2006
Amphion has made excellent progress so far this year. We have seen successful fund raisings for Supertron and Axcess during the period ended 30 June 2006 and FireStar post 30 June 2006. Also, we have hired a new chief executive officer for our Partner Company, Motif BioSciences.

In addition to our goal of developing thriving companies, part of our strategy is to liquidate our position once a company reaches a certain level of sustained growth and has generated a significant return on investment. For example one of our Partner Companies, Beijing Med-Pharm, has become a leading distributor of western pharmaceutical products in China. Since 1 January 2006, Amphion has sold 303,900 shares of Beijing Med-Pharm stock for US $1.28 million. Over the course of Amphion’s two-year investment in Beijing Med-Pharm, it realised a 3.66-fold return on its original investment.

We have also successfully begun the process of replacing our investment in Beijing Med-Pharm with an investment in Myconostica, a Manchester University spin-out that develops molecular probes for diagnosing infectious diseases. Currently there is no clinical solution on the market that allows for as fast and precise a diagnosis, and we look forward to adding Myconostica to our portfolio of companies.

The fair value of Amphion’s investment portfolio increased 21 percent for the period, signifying that Amphion is a company propelled by a strong underlying engine of growth. This continued growth allows Amphion to welcome one Partner Company per year to its portfolio while maintaining a portfolio of 7 to 10 Partner Companies at any one time. Amphion’s steady growth is attributable to its proven ability to identify market demands and Partner Companies that are positioned to answer those demands.

Amphion has addressed its capital needs with the close of a successful round of financing in August in which it raised gross proceeds of £1.04 million. The Company continues to hold US $1.7 million in Beijing Med Pharm stock, which is available to the Company to supplement its capital needs.


Partner Company Highlights
WellGen, Inc. is a nutrigenomics company using proprietary technology to discover and develop food and dietary supplements from plants and foods to market into the health and wellness markets. A spin-out of Rutgers University, WellGen has the exclusive worldwide license to a proprietary technology that screens food and plant extracts for their impact on gene expression associated with the onset or proliferation of cancer, arthritis, obesity and other human diseases.

WellGen’s leading anti-cancer and obesity compound extracted from orange peel, has its patents pending. The anti-cancer/obesity product has completed a short clinical trial in human patients with high-risk for colon cancer while a longer clinical trial is planned. Further pre-clinical and human studies of obesity and metabolic syndrome are being planned as well. There is a supply agreement in place for this product with Danisco, a Danish food ingredients company.

Clinical trials for the black tea extract in combination with glucosamine, a nutraceutical known to slow the progression of osteoarthritis, have been planned for 2006. The pilot studies will include 16 patients divided into three groups. Results of the trial are expected by year’s end.

During this period, we sadly reported the loss of WellGen’s CEO, David Evans, who unexpectedly passed away. WellGen’s management team, staff and all of its stakeholders honour his memory through their commitment to pushing the company he built to new heights.

Durham Scientific Crystals, Ltd. (DSC) is commercialising a patented process to produce single crystal wafers of the semi-conducting materials cadmium telluride and cadmium zinc telluride, which are used in digital X-ray cameras.

In addition to medical use, DSC is targeting the security industry for the use of its process. The recent scare at Heathrow International Airport in London demonstrated the urgency for enhanced X-ray technology. Currently, enhanced X-ray machines use a process that produces crystals from a liquid base. This process is characterised by poor yield and thus high costs. DSC’s process uses a vapour base, which achieves a higher yield, thus driving down the cost and allowing for widespread use.

DSC is working with non-commercial partners to optimise its crystals with an electrode edge that makes it easier to integrate them into the electronic infrastructure of scanners.

AXCESS International, Inc. is a leading provider of security and transportation logistics solutions that utilise radio frequency identification (RFID) technology. Its share price during the period increased US $0.45, from US $0.82 to US $1.27. The company raised US $3.5 million this year, including US $2.3 million during the period 1 January 2006 – 30 June 2006, and is using this capital for product development.

Motif BioSciences, Inc. is a population genetics company focused on discovering genes causing common diseases by utilising human genetic data from the Persian Gulf region.

During this period, Zaki Hosny, former vice president of marketing and operations for Europe, Middle East and Africa for Merck, was appointed chief executive officer of Motif. The Company also established a joint venture with the Shafallah Centre for Children with Special Needs, located in Doja, Qatar. Motif is playing a key role in the development of a state-of-the-art laboratory for the study of genetics.

The region’s founder population (people descended from a small number of common ancestors) provides a unique resource for the discovery of disease-related genes. Motif is recruiting 120 individuals for a pilot study that will help it understand the genetic architecture of this population and, in turn, identify the genetic pathways through which common disease-causing genes (i.e. rare monogenetic diseases, type 2 diabetes, obesity and asthma) pass from generation to generation. Motif is also studying and comparing the genetic architecture of whole families that have a high prevalence of these disorders.

FireStar Software, Inc. develops solutions that allow for the seamless automation of cross-platform transactions between multiple companies. FireStar’s flagship product, EdgeNode, began shipping in December 2005.

In August, FireStar raised US $2 million through an over-subscribed, Series E-1 preferred stock offering. It plans to use this capital to accelerate sales and marketing efforts for EdgeNode and for application development in payment systems, trading and health records exchange.

In addition, the company is working to extract value from its intellectual property portfolio.

Supertron Technologies, Inc. develops, manufactures and markets electronic components and systems for the magnetic resonance imaging (MRI) industry. Its products are based on superconductors and are designed for use in pre-clinical, clinical and research settings, including neurological, orthopaedic, cardiac, drug and image guided therapies.

Supertron’s MRI coils, the scanner’s “camera”, have demonstrated that they are capable of dramatically improving the imaging capabilities of a MRI scanner. The company is developing a cryogenic coil that increases speed and allows for imaging of body parts in motion. The cryogenic coil also improves resolution, which enables doctors to see smaller structures.

In July, Supertron closed on a US $3.5 million Series C financing, which was over subscribed.

Please visit our Portfolio page for more information on Partner Companies.


Outlook and Summary
In 2006, Amphion has delivered strong progress in all of its Partner Companies, as is seen with the rise in net asset value and fair value. The year has shown successful investments of more than $8 million in the portfolio, and also Amphion has continued to build up Partner Company management teams with the hire of a new chief executive for Motif Biosciences. The latest planned addition to the portfolio of Myconostica Ltd. has shown Amphion’s commitment in finding new and exciting opportunities within the universities and dedication to the strategy of continuing to invest in 7 to 10 companies.

The strong start to the year has provided Amphion with a solid base to continue to deliver on its strategy, and the prospects look encouraging with strong newsflow and exciting developments coming from the Partner Companies and further investments expected.